Developer docs
API playgroundTry for free, no card

Search company profiles

Diaclone

Full company profile

uuid0028qe2

Namestring
Diaclone
Legal namestring
Diaclone
Websiteurl
diaclone.com
Company typeenum
Private
Founded yearint
1986
Descriptiontext

Diaclone is a provider of raw material monoclonal and polyclonal antibodies, antigens, and ELISA/ELISpot/Fluorospot immunoassay kits used in inflammation, oncology, and immunology research and diagnostic applications. Its technology stack centers on hybridoma-derived antibodies and immunoassay formats — ELISA for sensitive quantification of native and recombinant proteins, and ELISpot/Fluorospot for single-cell-level cytokine secretion analysis — supported by contract manufacturing, contract development, and contract analytical services for IVD raw materials. The company served four primary B2B verticals — Life Science, IVD, Pharma, and Veterinary companies — through a sales-led motion via online ordering and distribution partnerships.

In July 2021, Diaclone was acquired by Medix Biochemica, a Finnish in vitro diagnostics raw material supplier with global operations. As a result, Diaclone no longer operates as an independent entity; its products and scientific capabilities have been integrated into Medix Biochemica's broader catalog spanning more than 15 clinical areas (cardiac markers, infectious diseases, tumor markers, neurology, and others), and are distributed through Medix Biochemica's global e-commerce storefront and international distributor network, including dedicated regional operations such as cnmedixbiochemica.com in China. The acquisition was framed by Medix Biochemica as a means of expanding its monoclonal antibody portfolio and strengthening its Western Europe presence. No independent operating financials, founding date, or headcount were disclosed in the available source material.

Short descriptiontext

Diaclone provided raw material monoclonal and polyclonal antibodies and ELISA/ELISpot/Fluorospot immunoassay kits for inflammation, oncology, and immunology applications, serving Life Science, IVD, Pharma, and Veterinary companies. Since July 2021 it has operated as an integrated brand within Medix Biochemica.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBesançon, France
HQ citystring
Besançon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
monoclonal antibodies, polyclonal antibodies, immunoassay kits, ELISA reagents, IVD raw materials
Industry2 codes
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
IVD Raw Materials
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Antibody Products
TypeOne Time License
Description

Sale of raw material monoclonal and polyclonal antibodies for immunoassay applications

info.medixbiochemica.com
2Immunoassay Kits
TypeOne Time License
Description

Sale of ELISA, ELISpot and Fluorospot kits for research use

info.medixbiochemica.com
3Custom Services
TypeProfessional Services
Description

Contract-based services including contract manufacturing, development and analytical services

info.medixbiochemica.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Diaclone manufactured and supplied raw material monoclonal and polyclonal antibodies, antigens, and immunoassay kits (ELISA, ELISpot, and Fluorospot) for research use in inflammation, oncology, and immunology. The company also offered contract manufacturing, contract development, and contract analytical services supporting IVD raw material production. Following the July 2021 acquisition by Medix Biochemica, all products are now sold under the Medix Biochemica portfolio.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Diaclone offers a portfolio of monoclonal and polyclonal antibodies, antigens, and immunoassay kits (ELISA, ELISpot, and Fluorospot) for research use in immunology, inflammation, oncology, and veterinary applications. Now integrated into Medix Biochemica following the July 2021 acquisition, these products serve Life Science, IVD, Pharma, and Veterinary companies. The company also provides contract-based services including contract manufacturing, development, and analytical services. Diaclone products are now accessible through Medix Biochemica's global distribution network and product catalog.

Product and service1 record
1Monoclonal and Polyclonal Antibodies
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Medix Biochemica
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Medix Biochemica acquired Diaclone in July 2021, a well-established provider of raw material monoclonal antibodies and ELISA/ELISpot immunoassays in inflammation, oncology and immunology. This acquisition expanded Medix Biochemica's portfolio with complementary scientific and technological capabilities and strengthened the company's Western Europe presence. All Diaclone products are now integrated into Medix Biochemica's product portfolio.

info.medixbiochemica.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diaclone

IVD Raw Materialsdiaclone.com

Diaclone provided raw material monoclonal and polyclonal antibodies and ELISA/ELISpot/Fluorospot immunoassay kits for inflammation, oncology, and immunology applications, serving Life Science, IVD, Pharma, and Veterinary companies. Since July 2021 it has operated as an integrated brand within Medix Biochemica.

What Diaclone does

Diaclone is a provider of raw material monoclonal and polyclonal antibodies, antigens, and ELISA/ELISpot/Fluorospot immunoassay kits used in inflammation, oncology, and immunology research and diagnostic applications. Its technology stack centers on hybridoma-derived antibodies and immunoassay formats — ELISA for sensitive quantification of native and recombinant proteins, and ELISpot/Fluorospot for single-cell-level cytokine secretion analysis — supported by contract manufacturing, contract development, and contract analytical services for IVD raw materials. The company served four primary B2B verticals — Life Science, IVD, Pharma, and Veterinary companies — through a sales-led motion via online ordering and distribution partnerships.

In July 2021, Diaclone was acquired by Medix Biochemica, a Finnish in vitro diagnostics raw material supplier with global operations. As a result, Diaclone no longer operates as an independent entity; its products and scientific capabilities have been integrated into Medix Biochemica's broader catalog spanning more than 15 clinical areas (cardiac markers, infectious diseases, tumor markers, neurology, and others), and are distributed through Medix Biochemica's global e-commerce storefront and international distributor network, including dedicated regional operations such as cnmedixbiochemica.com in China. The acquisition was framed by Medix Biochemica as a means of expanding its monoclonal antibody portfolio and strengthening its Western Europe presence. No independent operating financials, founding date, or headcount were disclosed in the available source material.

Diaclone firmographics

Firmographics
Name
Diaclone
Legal name
Diaclone
Website
https://diaclone.com
Company type
Private
Founded year
1986
Operating status
Acquired
Headcount range
11–50 employees
Short description
Diaclone provided raw material monoclonal and polyclonal antibodies and ELISA/ELISpot/Fluorospot immunoassay kits for inflammation, oncology, and immunology applications, serving Life Science, IVD, Pharma, and Veterinary companies. Since July 2021 it has operated as an integrated brand within Medix Biochemica.
Ownership category
akta.pro rank

Diaclone industry classification

Industry
Product category
IVD Raw Materials
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Monoclonal antibodies
  • Polyclonal antibodies
  • Immunoassay kits
  • ELISA reagents
  • IVD raw materials

Where Diaclone is headquartered

Location

Headquarters

HQ city
Besançon
HQ country
France
HQ region
Europe

Markets served

Diaclone business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Antibody Products: Sale of raw material monoclonal and polyclonal antibodies for immunoassay applications
  2. Immunoassay Kits: Sale of ELISA, ELISpot and Fluorospot kits for research use
  3. Custom Services: Contract-based services including contract manufacturing, development and analytical services

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Diaclone product offering

Product offering

Core offering

Diaclone manufactured and supplied raw material monoclonal and polyclonal antibodies, antigens, and immunoassay kits (ELISA, ELISpot, and Fluorospot) for research use in inflammation, oncology, and immunology. The company also offered contract manufacturing, contract development, and contract analytical services supporting IVD raw material production. Following the July 2021 acquisition by Medix Biochemica, all products are now sold under the Medix Biochemica portfolio.

Product overview

Diaclone offers a portfolio of monoclonal and polyclonal antibodies, antigens, and immunoassay kits (ELISA, ELISpot, and Fluorospot) for research use in immunology, inflammation, oncology, and veterinary applications. Now integrated into Medix Biochemica following the July 2021 acquisition, these products serve Life Science, IVD, Pharma, and Veterinary companies. The company also provides contract-based services including contract manufacturing, development, and analytical services. Diaclone products are now accessible through Medix Biochemica's global distribution network and product catalog.

Differentiator

Problem solved

Functional benefit

Products and services

  • Monoclonal and Polyclonal Antibodies

Companies that use Diaclone

Customer profile

Segments4 records

Ideal customer profiles4 records

Diaclone technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Diaclone partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Medix BiochemicacoreStrategic or Co-development Partner · 1 July 2021Medix Biochemica acquired Diaclone in July 2021, a well-established provider of raw material monoclonal antibodies and ELISA/ELISpot immunoassays in inflammation, oncology and immunology. This acquisition expanded Medix Biochemica's portfolio with complementary scientific and technological capabilities and strengthened the company's Western Europe presence. All Diaclone products are now integrated into Medix Biochemica's product portfolio.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Diaclone competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Diaclone financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diaclone leadership team

Management profile

Number of profiles

Diaclone funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diaclone M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diaclone

What does Diaclone do?

Diaclone manufactured and supplied raw material monoclonal and polyclonal antibodies, antigens, and immunoassay kits (ELISA, ELISpot, and Fluorospot) for research use in inflammation, oncology, and immunology. The company also offered contract manufacturing, contract development, and contract analytical services supporting IVD raw material production. Following the July 2021 acquisition by Medix Biochemica, all products are now sold under the Medix Biochemica portfolio.

Is Diaclone a public or private company?

Diaclone is a private company. It is classified as corporate owned and is currently acquired.

When was Diaclone founded?

Diaclone was founded in 1986. It employs 11 to 50 people.

Where is Diaclone based?

Diaclone is headquartered in Besançon, France, in the Europe region.

How does Diaclone make money?

Three revenue lines are on record. Antibody Products are the primary driver. The others are immunoassay Kits and custom Services.

Does Diaclone have an API?

No public API is recorded for Diaclone.

What industry is Diaclone in?

Diaclone's product category is IVD Raw Materials. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAGAGAI, Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals